News
C4 Therapeutics, Inc. (C4T) announced promising results from the latest data on its investigational drug cemsidomide for treating multiple myeloma, showing a 50% overall response rate (ORR) at the ...
TipRanks on MSN
C4 Therapeutics initiated with an Overweight at Barclays
Barclays initiated coverage of C4 Therapeutics (CCCC) with an Overweight rating and $8 price target The company’s lead asset, cemsidomide is an ...
C4T has completed enrollment and dose escalation for its Phase 1 trial of cemsidomide in MM ... additional detail on the company’s planned next steps of clinical development. C4 Therapeutics (C4T) ...
C4 Therapeutics (CCCC) announced that its partner Biogen (BIIB) has had its investigational new drug, IND, application for BIIB142 accepted by the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback